Medigen Biotechnology (3176.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan · ISIN TW0003176004

Price

33.25 TWD

Market cap

4.63 bn TWD

P/E (2025)

–

P/S (2025)

2.93

Dividend yield

0.00 %

Net margin

-6.88 %

Return on equity (ROE)

-2.31 %

Return on assets (ROA)

-1.76 %

Medigen Biotechnology financials

Fiscal year	2024	2025
Revenue	1.37 bn TWD	1.58 bn TWD
Gross profit	753.76 m TWD	905.02 m TWD
Operating income	-210.72 m TWD	-105.03 m TWD
EBIT	-76.33 m TWD	-195.47 m TWD
Net income	-204.69 m TWD	-108.80 m TWD

Full history since 2003, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1990 and is headquartered in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.